Please login to the form below

Not currently logged in
Email:
Password:

Pharma R&D spend down on 2009

According to new research, annual pharma spending in research and development fell for the first time ever from 2009 to 2010

According to new research, annual pharma spending in research and development fell for the first time ever from 2009 to 2010.

The review, compiled by CMR International, claims that expenditure on developing new medicines decreased three per cent from $70bn in both 2008 and 2009 to $68bn in 2010.

Other figures  to show a drop from 2009 to 2010 included the number of drugs entering phase I and phase II development, falling 47 per cent and 53 per cent respectively. The amount of new molecular entities launched also fell, with 21 launched in 2010 compared to 21 in 2009.

Pfizer is one of the main firms to limit R&D spending, with its budget to be cut by a quarter over the next two years. This includes the closure of a plant in Kent, England with the loss of 2,400 jobs.

One of the main issues for pharma companies in upcoming years is the loss of patent exclusivity for 110 drugs in the US, including 14 "blockbusters".

This has led many companies to use the alternative strategy of in-licensing or acquiring compounds. This area is facing difficulty too however, with self-produced drugs currently having a 20 per cent higher chance of making it to market.

27th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics